2021
Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis
He S, Li G, Schätzlein AG, Humphrey PA, Weiss RM, Uchegbu IF, Martin DT. Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis. Cellular Signalling 2021, 81: 109931. PMID: 33529758, DOI: 10.1016/j.cellsig.2021.109931.Peer-Reviewed Original ResearchConceptsBladder cancer cellsCancer cellsHuman bladder cancer specimensCisplatin-based chemotherapyBladder cancer treatmentBladder cancer specimensChemoresistant bladder cancer cellsBreast cancer cellsCell viabilityBladder cancerCancer specimensSmall molecule inhibitorsLevels of Ku70Cancer treatmentKu70 expression
2019
Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth
Li X, He S, Tian Y, Weiss RM, Martin DT. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. Cellular Signalling 2019, 63: 109381. PMID: 31374291, DOI: 10.1016/j.cellsig.2019.109381.Peer-Reviewed Original ResearchMeSH KeywordsButadienesCarcinoma, Transitional CellCell Line, TumorCell MovementCell SurvivalDrug Resistance, NeoplasmDrug SynergismEnzyme InhibitorsGene Expression Regulation, NeoplasticGlycoproteinsHumansHydrazinesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1NitrilesQuinoxalinesUrinary Bladder NeoplasmsConceptsChemoresistant bladder cancerBladder cancer cellsBladder cancerInterleukin-6Clinical outcomesMultidrug resistanceGemcitabine-resistant bladder cancer cellsBladder cancer cell growthMajor treatment obstacleMetastatic bladder cancerPI3K/Akt/mTOR signalingCancer cellsResistant bladder cancer cellsPoor clinical outcomeAkt/mTOR SignalingSynergistic inhibitionNovel therapeutic strategiesPotential therapeutic targetMEK/ERK signalingCancer cell growthRaf/MEK/ERK signalingRole of gp130Therapeutic strategiesTreatment obstaclesTherapeutic target
2015
Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth
Martin D, Steinbach J, Saltzman W, Weiss R. Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.889.11.Peer-Reviewed Original ResearchBacillus Calmette-GuerinExpression of gp130Bladder cancer cellsBladder cancerCancer specimensNon-muscle invasive bladder cancerCancer cellsEffective adjuvant agentInvasive bladder cancerWeeks of treatmentBladder cancer tissue microarrayBladder cancer growthComprehensive cancer centerBladder cancer specimensCancer tissue microarrayHuman bladder cancerAdjuvant agentBladder tumorsCancer CenterCytokeratin 20Signal transduction pathwaysCalmette-GuerinTumor gradeTissue microarrayCarcinoma markers
2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine Nanotechnology Biology And Medicine 2013, 9: 1124-1134. PMID: 23764660, PMCID: PMC3815967, DOI: 10.1016/j.nano.2013.05.017.Peer-Reviewed Original ResearchConceptsHistone deacetylase inhibitor belinostatBladder cancerBladder permeability barrierNon-invasive bladder cancerCultured bladder cancer cellsBladder cancer cellsChemotherapy efficacyIntravesical drug deliveryXenograft tumorsMouse bladderMouse modelConvincing dataHuman ureterBelinostatCancerCancer cellsLower IC50TumorsAcetyl-H4Tissue penetrationCLINICAL EDITORIntracellular uptakeDeliveryCellsPatients
2011
MP-04.16 Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse Bladder
Weiss R, Martin D, Steinbach J, Liu J, Kaimakliotis H, Wheeler M, Hittelman A, Saltzman W. MP-04.16 Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse Bladder. Urology 2011, 78: s55. DOI: 10.1016/j.urology.2011.07.090.Peer-Reviewed Original ResearchBladder cancer cells1055 SURFACE MODIFICATIONS OF POLY(LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CAN INCREASE ITS UPTAKE BY BLADDER CANCER CELLS
Martin D, Steinbach J, Kaimakliotis H, Liu J, Wheeler M, Hittelman A, Saltzman W, Weiss R. 1055 SURFACE MODIFICATIONS OF POLY(LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CAN INCREASE ITS UPTAKE BY BLADDER CANCER CELLS. Journal Of Urology 2011, 185: e424. DOI: 10.1016/j.juro.2011.02.1092.Peer-Reviewed Original ResearchBladder cancer cellsCancer cells
2010
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C
Verma A, DeGrado J, Hittelman AB, Wheeler MA, Kaimakliotis HZ, Weiss RM. Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. BJU International 2010, 107: 1154-1161. PMID: 20735383, DOI: 10.1111/j.1464-410x.2010.09543.x.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorVascular endothelial growth factor receptor 2Bladder cancer cellsVEGF receptor 1Bladder of ratsEndothelial growth factorVEGFR-2 mRNAMitomycin CVEGFR-2 proteinCancer cellsSurvivin siRNAVEGF concentrationsMMC concentrationsUrinary vascular endothelial growth factorGrowth factorVEGFR-2 concentrationsGrowth factor receptor 2Superficial bladder cancerTransitional cell carcinomaMMC treatmentEndothelial growth factor receptor 2Factor receptor 2Interleukin-6 mRNAEffective intravesical treatmentLower MMC concentrations436 EFFECT OF SURVIVIN SIRNA AND VEGF SIRNA COMPLEXED IN NANOPARTICLES ON BLADDER CANCER CELLS AND UROTHELIAL TISSUES
Saltzman A, Woodrow K, Wheeler M, Verma A, Saltzman W, Weiss R. 436 EFFECT OF SURVIVIN SIRNA AND VEGF SIRNA COMPLEXED IN NANOPARTICLES ON BLADDER CANCER CELLS AND UROTHELIAL TISSUES. Journal Of Urology 2010, 183: e172-e173. DOI: 10.1016/j.juro.2010.02.507.Peer-Reviewed Original Research1153 EFFECT OF MITOMYCIN C ON LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS IN BLADDER CANCER CELLS AND IN BLADDERS OF RATS INTRAVESICALLY INSTILLED WITH MITOMYCIN C
Verma A, Wheeler M, DeGrado J, Kaimakliotis H, Hittelman A, Weiss R. 1153 EFFECT OF MITOMYCIN C ON LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS IN BLADDER CANCER CELLS AND IN BLADDERS OF RATS INTRAVESICALLY INSTILLED WITH MITOMYCIN C. Journal Of Urology 2010, 183: e446-e447. DOI: 10.1016/j.juro.2010.02.652.Peer-Reviewed Original Research
2003
Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma
Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003, 62: 162-166. PMID: 12837459, DOI: 10.1016/s0090-4295(03)00134-1.Peer-Reviewed Original ResearchConceptsUrinary IL-8 levelsIL-8 levelsTransitional cell carcinomaBacille Calmette-GuérinIL-8Cell carcinomaCalmette-GuérinProstate cancerHealthy subjectsActive transitional cell carcinomaUrinary interleukin-8 levelsLow stage transitional cell carcinomaInterleukin-8 levelsBladder cancer cell linesBladder cancer cellsEnzyme-linked immunosorbentCancer cell linesIntravesical therapyInflammatory processInvasive tumorsAngiogenic factorsMitomycin CElevated levelsCancer cellsMitomycin C.